NASDAQ$HWKN
Hawkins Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Hawkins reported record fourth quarter sales and EPS, driven by increased selling prices and strong performance in the Water Treatment segment.
Hawkins, Inc. reported record fourth quarter sales of $228.1 million and diluted EPS of $0.55. Adjusted EBITDA increased by 21% compared to the same period of the prior year. The company's strong operating cash flow allowed it to pay down $19 million in debt during the quarter.
- Record fourth quarter sales of $228.1 million.
- Record fourth quarter diluted earnings per share (EPS) of $0.55, 10% higher than the same period of the prior year.
- Adjusted EBITDA of $27.0 million, a 21% increase over the same period of the prior year.
- Record fourth quarter operating cash flow allowed the company to pay down $19 million in debt.
Headline financials
Revenue & EPS history
Hawkins · Revenue · Quarterly
$228M
Revenue by segment
Hawkins · $228M total across 3 segments · Q4 2023
- Industrial Solutions$118M+0.3%51.6%
- Water Treatment$71.4M+19.0%31.3%
- Food & Health Sciences$39.1M-14.3%17.1%
Forward guidance
Hawkins expects continued top and bottom-line growth in its Water Treatment segment. The company is cautiously optimistic about its Industrial segment, but believes economic pressures will continue to weigh on many of its customers and impact demand. In Health and Nutrition, the company expects the decline seen in the latter half of fiscal 2023 to continue through much of fiscal 2024.
Tailwinds
- Continued top and bottom-line growth expected in Water Treatment segment.
- Expanding geographic footprint positions the company well for continued growth in Water Treatment.
- Company believes it will continue to generate strong operating cash flow.
- Company will continue to pay down debt during fiscal year 2024.
- Diversity of businesses and overall strength of the company.
Headwinds
- Economic pressures expected to weigh on Industrial segment customers and impact demand.
- Decline in Health and Nutrition segment expected to continue through much of fiscal 2024.
- Consumer demand for health and immunity products declined from the COVID-bump high.
- Customers are working through excess inventory in the Health and Nutrition segment.
- Continued raw material cost increases.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+0.7%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+5.6%
Avg return
30 days after
56%
36 / 64 earnings
Positive
+17.6%
Q1 2025
Best reaction
-10.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.2% | -5.5% | -2.1% | |
| Q3 2026 | -9.1% | -17.6% | -3.0% | |
| Q2 2026 | -5.0% | -19.0% | -18.0% | |
| Q4 2025 | -0.7% | +5.8% | +13.5% | |
| Q3 2025 | -8.4% | -0.1% | -9.6% | |
| Q2 2025 | -8.8% | -9.3% | +14.8% | |
| Q1 2025 | +17.6% | +11.1% | +22.8% | |
| Q4 2024 | +9.4% | +15.4% | +13.1% | |
| Q3 2024 | -10.2% | -13.5% | +1.7% | |
| Q2 2024 | -5.1% | +5.8% | +9.0% | |
| Q1 2024 | +7.1% | +10.2% | +35.9% | |
| Q4 2023 | +12.3% | +9.1% | +15.4% | |
| Q3 2023 | +9.8% | +5.5% | +8.1% | |
| Q2 2023 | -2.3% | -9.5% | -9.6% | |
| Q1 2023 | +3.9% | +7.4% | -1.7% | |
| Q4 2022 | -7.5% | -10.5% | -7.2% | |
| Q3 2022 | +9.4% | +5.8% | +23.9% | |
| Q2 2022 | -7.1% | -4.7% | -11.6% | |
| Q1 2022 | +14.9% | +12.4% | +22.3% | |
| Q4 2021 | +4.0% | +2.5% | -0.3% | |
| Q3 2021 | +9.7% | +11.5% | +25.1% | |
| Q2 2021 | +3.8% | -5.8% | +2.6% | |
| Q1 2021 | +2.1% | +8.7% | +7.5% | |
| Q4 2020 | +9.3% | +14.9% | +11.0% | |
| Q3 2020 | +0.7% | +0.9% | -6.7% | |
| Q2 2020 | +4.0% | +7.9% | +0.6% | |
| Q1 2020 | +0.5% | +3.9% | -1.3% | |
| Q4 2019 | +4.5% | +4.1% | +15.5% | |
| Q3 2019 | -10.1% | -14.2% | -7.4% | |
| Q2 2019 | +10.5% | +9.0% | +22.9% | |
| Q1 2019 | +9.8% | +9.2% | +10.7% | |
| Q4 2018 | -6.9% | -3.1% | +4.9% | |
| Q3 2018 | +3.2% | +5.7% | +5.7% | |
| Q2 2018 | -2.4% | -5.9% | -1.0% | |
| Q1 2018 | -4.4% | -7.0% | -15.6% | |
| Q4 2017 | +1.4% | +1.6% | -1.1% | |
| Q3 2017 | +0.5% | +2.0% | -4.6% | |
| Q2 2017 | +0.7% | +3.8% | +21.6% | |
| Q1 2017 | +2.4% | +4.0% | +4.3% | |
| Q4 2016 | +10.5% | +12.2% | +11.3% | |
| Q3 2016 | +0.3% | — | — | |
| Q2 2016 | +1.1% | — | — | |
| Q1 2016 | +0.3% | — | — | |
| Q4 2015 | +2.2% | — | — | |
| Q3 2015 | -2.4% | — | — | |
| Q2 2015 | +2.5% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -1.8% | — | — | |
| Q3 2014 | -2.0% | — | — | |
| Q2 2014 | -5.5% | — | — | |
| Q1 2014 | -6.6% | — | — | |
| Q4 2013 | -1.8% | — | — | |
| Q3 2013 | +0.3% | — | — | |
| Q2 2013 | +0.8% | — | — | |
| Q1 2013 | +1.9% | — | — | |
| Q4 2010 | -3.1% | — | — | |
| Q4 2012 | -3.1% | — | — | |
| Q3 2011 | +3.2% | — | — | |
| Q3 2012 | +3.2% | — | — | |
| Q2 2012 | +2.5% | — | — | |
| Q1 2012 | -3.3% | — | — | |
| Q1 2011 | -3.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q4 2011 | -3.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro